Please assess the completion status of the following clinical trial:

Trial Title: A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Type Ⅱ diabetes mellitus~2. Non-alcoholic fatty liver disease: subjects who have CAP(Controlled Attenuation Parameter) ≥ 250dB/m measured by transient elastography (fibroscan) at screening test~3. Age ≥ 20 years~4. Patients who have not been taking any oral hypoglycemic agent for more than 12 weeks with HbA1c 7.0 to 8.5% at screening test or who have been taking metformin monotherapy for at least 8 weeks with HbA1c 7 to 9% at screening test~5. Agreement with written informed consent~Exclusion Criteria:~1. Patients whose alcohol consumption \>210g/week for males and 140g/week for females~2. chronic B viral hepatitis, chronic C viral hepatitis, Type I diabetes, or secondary diabetes~3. having a history of acute or chronic metabolic acidosis including diabetic ketoacidosis~4. patients who have been taking other oral hypoglycemic agents except metformin or insulin within recent 8 weeks~5. who experienced hypersensitivity reaction against metformin or glitazone drugs~6. who has been treated with corticosteroids for at least 14 days within 2 month prior to Screening~7. having a history of lactic acidosis~8. having genetic predispositions such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption~9. who are in condition of malnutrition, starvation, cachexia, severe infection, major trauma, hypopituitarism, or adrenal insufficiency~10. diagnosed with cancer within 2 years or having chemo or radiotherapy for cancer treatment~11. a history of drug abuse or chronic alcoholism~12. a history of heart failure (NYHA class III and IV) or uncontrolled arrhythmia~13. a history of acute cardiovascular or cerebrovascular disease within 12 weeks prior to Screening (unstable angina, myocardial infarction, transient ischemic attack, cerebral infarct, cerebral hemorrhage, coronary bypass, percutaneous coronary intervention)~14. Renal dysfunction: Serum creatinine greater than 1.5mg/dl for males and 1.4mg/dl for females.~15. Anemia less than 10.5g/dl for any reason~16. Pregnant women or nursing mothers~17. Fertile women who not practice contraception with appropriate methods~18. in treatment concomitant drug from other clinical trials within 4 weeks from enrollment~19. who did not agree with written informed consent

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lobeglitazone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).